BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12386638)

  • 1. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.
    Raaska K; Niemi M; Neuvonen M; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2002 Oct; 72(4):362-9. PubMed ID: 12386638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
    Varis T; Kivistö KT; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
    Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.
    Varis T; Kaukonen KM; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1998 Oct; 64(4):363-8. PubMed ID: 9797792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of itraconazole on the pharmacokinetics of inhaled lidocaine.
    Isohanni MH; Neuvonen PJ; Olkkola KT
    Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):120-3. PubMed ID: 15447735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Itraconazole increases plasma concentrations of quinidine.
    Kaukonen KM; Olkkola KT; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Nov; 62(5):510-7. PubMed ID: 9390107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.
    Tapaninen T; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
    J Clin Pharmacol; 2011 Mar; 51(3):359-67. PubMed ID: 20400651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.
    Niemi M; Tornio A; Pasanen MK; Fredrikson H; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2006 Jun; 62(6):463-72. PubMed ID: 16758263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid.
    Neuvonen PJ; Jalava KM
    Clin Pharmacol Ther; 1996 Jul; 60(1):54-61. PubMed ID: 8689812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
    Kivistö KT; Wang JS; Backman JT; Nyman L; Taavitsainen P; Anttila M; Neuvonen PJ
    Eur J Clin Pharmacol; 2001 Apr; 57(1):37-42. PubMed ID: 11372588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.
    Varis T; Backman JT; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Mar; 67(3):215-21. PubMed ID: 10741623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers.
    Varis T; Kivistö KT; Backman JT; Neuvonen PJ
    Pharmacol Toxicol; 1999 Jul; 85(1):29-32. PubMed ID: 10426160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan.
    Antila S; Honkanen T; Lehtonen L; Neuvonen PJ
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):446-9. PubMed ID: 9726699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the systemic effects of budesonide inhaled from Easyhaler and from Turbuhaler in healthy male volunteers.
    Hämäläinen KM; Granander M; Toivanen P; Malinen A
    Respir Med; 2001 Nov; 95(11):863-9. PubMed ID: 11716199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
    Karonen T; Laitila J; Niemi M; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2012 May; 68(5):681-8. PubMed ID: 22108774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
    Neuvonen PJ; Kantola T; Kivistö KT
    Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.
    Varis T; Kivistö KT; Neuvonen PJ
    Eur J Clin Pharmacol; 2000 Apr; 56(1):57-60. PubMed ID: 10853878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.
    Niemi M; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2001 Jul; 70(1):58-65. PubMed ID: 11452245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine.
    Isohanni MH; Neuvonen PJ; Palkama VJ; Olkkola KT
    Eur J Clin Pharmacol; 1998 Sep; 54(7):561-5. PubMed ID: 9832299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.